Celltrion chairman’s sell-out plan boosts stock price

Published: 2013-04-18 06:58:00

Updated: 2013-04-18 06:58:00

Celltrion chairman Seo Jung-jin announces Tuesday his plan to sell all of his stakes in the Kosdaq’s No. 1 market cap company and its affiliates to a multinational pharmaceutical company, citing predatory short-selling as the main reason behind the move.

Shares of Celltrion jumped 5 percent on...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK